Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
- Associated Therapies
- -
Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT00601614
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 25
- Registration Number
- NCT00597116
- Locations
- 🇨ðŸ‡
Research Site, Zurich, Switzerland
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 164
- Registration Number
- NCT00537095
- Locations
- 🇨ðŸ‡
Research Site, Bern, Switzerland
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- Branimir Sikic
- Target Recruit Count
- 13
- Registration Number
- NCT00532909
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00514046
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 67
- Registration Number
- NCT00508001
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Phase I Chinese PK
- Conditions
- Interventions
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 36
- Registration Number
- NCT00503711
- Locations
- 🇨🇳
Research Site, Guangzhou, China
A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 109
- Registration Number
- NCT00500292
- Locations
- 🇨🇳
Research Site, Tao-Yuan, Taiwan
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00496665
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 1
- Registration Number
- NCT00481845
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.